



Published in final edited form as:

J Addict Res Ther. ; Suppl 4: . doi:10.4172/2155-6105.S4-012.

Caffeinated Alcoholic Beverages – An Emerging Trend in Alcohol Abuse

Kelle M Franklin*, Sheketha R Hauser, Richard L. Bell, and Eric A Engleman

Institute of Psychiatric Research, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Abstract

Alcohol use disorders are pervasive in society and their impact affects quality of life, morbidity and mortality, as well as individual productivity. Alcohol has detrimental effects on an individual's physiology and nervous system, and is associated with disorders of many organ and endocrine systems impacting an individual's health, behavior, and ability to interact with others. Youth are particularly affected. Unfortunately, adolescent usage also increases the probability for a progression to dependence. Several areas of research indicate that the deleterious effects of alcohol abuse may be exacerbated by mixing caffeine with alcohol. Some behavioral evidence suggests that caffeine increases alcohol drinking and binge drinking episodes, which in turn can foster the development of alcohol dependence. As a relatively new public health concern, the epidemiological focus has been to establish a need for investigating the effects of caffeinated alcohol. While the trend of co-consuming these substances is growing, knowledge of the central mechanisms associated with caffeinated ethanol has been lacking. Research suggests that caffeine and ethanol can have additive or synergistic pharmacological actions and neuroadaptations, with the adenosine and dopamine systems in particular implicated. However, the limited literature on the central effects of caffeinated ethanol provides an impetus to increase our knowledge of the neuroadaptive effects of this combination and their impact on cognition and behavior. Research from our laboratories indicates that an established rodent animal model of alcoholism can be extended to investigate the acute and chronic effects of caffeinated ethanol.

Keywords

Alcohol; Caffeine; Caffeinated alcohol; Energy drink; Adenosine; Dopamine; Alcohol-preferring rat

Prevalence and Impact of Alcohol use Disorders

Extensive evidence indicates that alcohol abuse has widespread social, economic, behavioral, and physiological consequences [1]. The Centers for Disease Control and

Copyright: © 2013 Franklin KM, et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Kelle M. Franklin, Indiana University School of Medicine, Institute of Psychiatric Research, 791 Union Drive, Indianapolis, IN 46202, USA, Tel: 1-317-278-4938; Fax: 1-317-274-1365; kmfrankl@iupui.edu.

Prevention (CDC) rank alcohol abuse as the third leading cause of preventable death [2]. For example, a causal relationship has been suggested between alcohol abuse and at least 50 different medical conditions [3]; also see [4] for a discussion on the role of genetics). According to the National Highway Traffic Safety Administration [5], nearly one-third of traffic fatalities in the United States involve at least one vehicle operator with a blood alcohol level (BAL) of at least 0.08 gram %, which is the legal BAL threshold for driving while impaired in the United States [6]. Direct and indirect costs of alcohol abuse have been estimated to approximate \$500 billion annually [7]. Over half of adult Americans have a close relative with an alcohol use disorder (AUD), and a subset of these individuals have this trait across multiple generations.

The gap between men and women in the prevalence of AUDs and episodes of intoxication has been decreasing among youth and the elderly [8,9]. Regardless of gender, recent years have witnessed an increase in alcohol-related problems, particularly in young drinkers [10–12]. This is a serious concern, as early onset of alcohol use is a significant risk factor in the development and time-course of alcohol dependence [13,14].

Binge drinking similarly has been associated with future alcohol dependence problems and with younger drinkers [15–17]. More than 70% of surveyed college students report having engaged in alcohol binge drinking during their high school years [17]. Alcohol drinking in underage drinkers aged 12–20 years accounts for 11% of alcohol consumption in the United States, with a majority of this intake occurring during binge drinking episodes [18]. Regarding post-college-age binge-drinking, 45% of Americans aged 21–25 report that they had engaged in alcohol binge drinking in the previous month [19]. Nearly half of all individuals meeting life-time diagnostic criteria for alcohol dependence do so by the age of 21 and this increases to approximately two-thirds by the age of 25 [20]. In summary, the association of binge drinking with the development of alcohol dependence is magnified by the propensity of young people to participate in this behavior.

Caffeine in the Context of Alcohol Abuse

Further complicating this issue is the common occurrence of consuming others drugs with alcohol. Polydrug use may introduce unique, complex cognitive and behavioral interactions that cannot be addressed by assessing the effects of each drug individually. Alcoholic populations exhibit an extremely high rate of poly-drug use [21]. One substance that is increasingly paired with alcohol is caffeine [22].

Caffeine (1,3-trimethylxanthine) is the United States' most used psychoactive substance [23,24]. Caffeine largely has been eschewed as a psychoactive drug, despite, or perhaps because of, its widespread use. The U.S. Food and Drug Administration (FDA) have categorized caffeine as an ingredient “generally recognized as safe” [22]. However, it is a mild psycho stimulant, with motor effects similar to more potent drugs of abuse, such as cocaine and amphetamine [25,26]. Despite basic and clinical evidence that caffeine is reinforcing [tolerance can develop to some of its effects, and cravings and mild withdrawal symptoms can ensue after cessation of consumption; [25,27–30], it is rarely considered a drug of abuse. Nevertheless, if dependence criteria, in their broadest sense, from the fourth

edition of the Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSM-IV-TR) [31] are used, a significant portion of the population would be considered dependent upon caffeine intake [32,33]. What is especially troubling is that, similar to alcohol, adolescents and young adults are especially prone to abuse caffeinated beverages [34–36].

Behavioral and genetic associations indicate that there is a significant link between caffeine and alcohol intake [37–42]. Regarding caffeine abuse by alcoholics, Zeiner et al. [43] reported that alcohol-dependent individuals consume approximately 30% more caffeine daily, compared to their non-alcoholic counterparts. In addition, reports suggest that detoxified alcoholics consume twice as much coffee following cessation of alcohol drinking, compared to their intake prior to treatment [44]. This could be a serious concern for treatment-seeking alcoholics. For example, using caffeine intake as a substitute stimulus for alcohol consumption could interfere with psychological and physiological efforts to overcome addiction-related behaviors. Further, it is unclear what impact, if any, a history of heavy alcohol drinking could have on caffeine's pharmacological profile, and whether this could affect the caffeine levels consumed by actively drinking and detoxified alcoholics. Assuming that caffeine and ethanol share at least some mechanisms of action, it is possible that physiological adaptations could generalize between the two substances. In addition, this elevated caffeine intake by alcoholics could be indicative of a more generalized physiological or genetic vulnerability to substance abuse and could mandate specialized treatment strategies.

In support of this latter suggestion, an assessment of adult twins indicates that ethanol and caffeine use disorders reflect approximately 50% heritability, although genetic loading for caffeine dependence may be lower than that for alcoholism [45–47]. In addition, poly-drug twin study analyses have reported a significant heritability effect on the co-use of ethanol and caffeine [48–50]. Similarly, Svikis et al. [51] reported that caffeine-dependent women who were family history positive (FHP) for alcoholism were less successful in reducing caffeine intake during pregnancy, relative to those who were family-history negative (FHN) for alcoholism. These authors [51] concluded that FHP individuals may require more intensive dependence intervention, due to a generalized vulnerability to heavy substance use. Within the context of dual-diagnosis, it is important to recognize that Bergin and Kendler [52] reported significant correlations (genetic and/or environmental) between caffeine use, tolerance and/or withdrawal and generalized anxiety, panic, phobic as well as major depressive disorders, conditions which also have been associated with heavy alcohol use.

Behavioral genetic reports indicating that a family history of alcoholism affects caffeine intake coincide with some pre-clinical findings in our laboratory. We performed experiments to investigate whether rats selectively bred for high alcohol preference also would display greater caffeine intake, relative to their progenitor stock. Alcohol-preferring (P) rats satisfy the criteria proposed for animal models of alcoholism, including consuming alcohol for its pharmacological effects and exhibiting signs of alcohol dependence and tolerance [53,54]. The genetically selected P rat shares some of the characteristics of FHP individuals, including early onset of excessive alcohol intake, lower sensitivity to the high-dose effects of alcohol and greater sensitivity to the behavioral and autonomic stimulating effects of low-dose alcohol, compared with NP (FHN) and outbred Wistar rats [55,56].

These rats exhibit neural and behavioral differences, as compared to nonpreferring NP counterparts and non-selected rats [57,58], such as performance of binge-like alcohol drinking behaviors [59–61]. P rats obtain pharmacologically relevant blood alcohol levels under several alcohol access conditions [57,59,61,62], and evidence supports the use of these animals to model human binge drinking [63].

Also similar to human alcoholics, P rats and other rodent models of alcoholism exhibit a greater general preference for some rewarding stimuli, such as illicit drugs, including nicotine [64] and 3,4-methylenedioxyamphetamine (ecstasy; [65], sucrose, and novelty, relative to non-preferring and non-selected rodent lines [e.g., 66–68]. Previous studies have reported that subjects selectively bred for high alcohol intake exhibit greater behavioral and neurochemical responses to psycho stimulants, compared to low alcohol drinking or non-selected lines. Hyytiä and Sinclair [69] reported that high alcohol-preferring Alko Alcohol (AA) rats consume more cocaine orally than do their alcohol non-preferring Alko, non-Alcohol (ANA) counterparts. Similarly, Wistar and AA rats behaviorally selected for high alcohol consumption exhibit increased conditioned place preference for cocaine [70,71], compared to their low drinking counterparts. Further, greater increases in cocaine-induced extracellular DA release in striatal compartments have been reported in Sardinian alcohol-preferring (sP) and AA rats, compared to alcohol non-preferring subjects [72,73]. Taken in conjunction with findings that high alcohol-preferring rat lines exhibit differential consumption of and neurobehavioral responses to other drugs of abuse beyond alcohol, such as cocaine and nicotine, compared to nonpreferring and nonselected counterparts, it is likely that these animals also could provide a useful model to examine caffeine intake.

Regarding the association of a genetic background for high alcohol preference with caffeine intake, we assessed female P rats and outbred Wistar rats for free-choice 24-hr intake of multiple concentrations (0.3 and 1.0 mg/ml) of caffeine and water over a 7-week period. These concentrations were selected from those used in a previous caffeine intake study [74]. From the human perspective, these concentrations amount to the difference between a 16-oz. serving of coffee from McDonald's® or Starbucks®, respectively [75]. We hypothesized that P rats would consume more total caffeine per day, vs. Wistar rats, and that the greatest differences would occur at the 1.0 mg/ml caffeine concentration.

At no time in the course of this study did either P or Wistar groups exhibit a preference for caffeine solution over water. It has been shown previously that a period of forced access to caffeine is needed to observe caffeine preference over water [76]. The results indicated that P rats consumed more total caffeine (mg/kg) per 24-hr period than Wistar rats, such that consumption levels were approximately 10.5 vs. 6.5 mg/kg/24 hr, respectively (Figure 1). Clinically, reports indicate that non-dependent humans consume about 4–5 mg caffeine/70 g body weight. In contrast to our a priori hypothesis, the majority of this difference was associated with the lower (0.3 mg/ml) caffeine concentration, whereas intake of the higher (1.0 mg/ml) concentration was approximately equal in the two rat lines. One possible explanation for this finding is that intake of the higher concentration may have been limited by its flavor profile in both rat lines. In contrast, the two rat lines may have exhibited differential intake of the lower caffeine concentration due to the pharmacological properties of the compounds. Similar line differences for concentration-dependent differences in

response to alcohol have been reported previously [77]. Overall, P rats consumed more caffeine than did outbred Wistar rats. This difference suggests that genetic selection for high alcohol preference also may have generated a propensity for elevated caffeine intake. These findings may provide additional validity for the use of the P animal model of alcoholism to examine ethanol co-abuse with other substances. Furthermore, this study provides basic research support for clinical findings indicating an association between alcohol and caffeine intake, which may be mediated by common reward neurocircuitry.

Caffeinated Alcoholic Beverages

The introduction of Red Bull® energy drink in the United States in 1997 sparked a surge in consumption of “energy drinks,” as well as energy drinks mixed with alcohol [78]. These products essentially combine purported performance-enhancing ingredients (e.g., guarana, taurine, ginseng, green tea extract, and/or B-complex vitamins) with high doses of caffeine (55 to 505 mg/serving) [78]. In comparison, 12- oz cans of Coca-Cola and Mountain Dew soft drinks contain 34 and 54 mg caffeine, respectively [79,80]. As a parallel to binge alcohol-drinking, approximately one-third of 12–24 year-olds consume energy drinks on a regular basis [81]. A reported decline in soft drink consumers between 2003 and 2008 likely reflects, in part, a doubling in the number of energy drink consumers during that same time frame [82].

As indicated above, an alarming trend is the addition of alcohol to these energy drinks. In general, marketing strategies for energy drinks have targeted young males [78], a group which also exhibits the greatest prevalence and frequency of alcohol binge drinking [83]. This is particularly of concern due to the lack of available information that addresses whether a history of heavy caffeine intake affects alcohol-related pharmacology and toxicology. With the wide acceptance of energy drinks, more and more drinking establishments and manufacturers have increased the caffeine content of their alcoholic beverages. The growing availability of high-caffeine energy drinks and pre-caffeinated alcoholic drinks has translated into high levels of caffeine and ethanol co-consumption. Young drinkers are the target market for many of these cocktails [84] and have contributed to their popularity [85]. Particularly concerning is that caffeinated alcoholic beverages may initiate earlier and more extreme caffeine and alcohol intake in younger populations. A 2006 web-based survey of ten colleges in North Carolina found that 24% of students who reported alcohol intake in the prior month had mixed alcohol with an energy drink [86]. Another sample of U.S. college students indicated that nearly half of survey respondents had consumed alcohol mixed with energy drink [84]. In Brazil, more than three-quarters of survey participants reported regular consumption of energy drinks mixed with alcohol [87], whereas in Turkey, the incidence in college students has been reported at 40% [88].

The popularity of these beverages has encouraged researchers to question what motivates their consumption. A standardized assessment of the impact of expectancies on motivation to consume these beverages indicated that caffeine was believed to enhance alcohol-related intoxication, a factor also associated with increased intake of the mixtures [89]. Caffeine and energy drinks have been reported to reduce ethanol-induced sedation or perception of sedation in humans and animals [87,90–92], although these findings have been mixed [93].

Consumption of caffeinated alcoholic beverages also increases reports of happiness and euphoria, behavioral disinhibition, and physical vigor, relative to alcohol alone [87,94].

However, just as individuals who consume large amounts of alcohol often underestimate how much alcohol affects them [95], increasing evidence indicates this may be compounded when these individuals consume caffeinated alcoholic beverages. Despite indications that young consumers of these drinks do not discount the risks of alcohol-related negative consequences when caffeine is co-consumed [89], some evidence in the U.S. and Canada indicates that adding caffeine to alcohol actually may increase these risks. Several reports indicate that caffeine co-administration increases alcohol intake and hazardous alcohol drinking [86,94,96,97]. Co-consumption of energy drinks and alcohol has been reported to triple the likelihood of binge alcohol drinking, relative to drinking alcohol alone [96]. O'Brien et al. [86] found that students who mixed alcohol and caffeine reported more heavy alcohol drinking episodes and twice as many episodes of weekly intoxication. A recent self-report study found that high-frequency energy drink consumers (>1/week) were heavier alcohol drinkers, drank alcohol more often, had greater risk for alcohol-related problems, and exhibited a higher risk of meeting DSM-IV criteria for alcohol dependence, relative to those with low or no energy drink consumption [97], but see comment by Skeen and Glenn [98]. Several reports indicate that consumers of caffeinated alcoholic beverages engage in more violent and risky behaviors, and experience more negative consequences, compared to those drinking alcohol alone. Particularly concerning are reports that consumers of caffeinated alcoholic beverages evidence more assaults (as perpetrators or victims), automobile incidents, and planned and actual alcohol-impaired driving episodes, relative to those drinking alcohol alone [86,99–101]. These negative consequences are particularly evident in adolescent populations [102].

It has been postulated that caffeine reduces perceived ethanol intoxication with little or no change to the cognitive impairing effects of ethanol [103,104], although this decrease may be task-dependent [105,106]. Expectations also could be involved in these findings. Evidence indicates that psychomotor tolerance to ethanol is increased in humans with a prior history of combining caffeine and ethanol, compared to individuals who have experienced either drug alone [107]. Moreover, this tolerance likely is, in part, an unconscious cognitive construct. Fillmore et al. [107] reported that informing subjects that caffeine would interfere with ethanol-induced sedation diminished caffeine's ability to do so, and Fillmore [108] suggested that the expectation that caffeine would interfere with ethanol-induced sedation could trigger compensatory physiological mechanisms to maintain the disruptive influence of ethanol. These results emphasize the role of cognitive processes in the physiological response to ethanol in human subjects.

With regard to motor functioning, Marczinski and Fillmore [109] and Marczinski et al. [110] presented evidence that caffeine attenuates ethanol-induced motor skill disturbances. In a cued go/no go task, consuming an energy drink along with ethanol was reported to improve reaction time for identifying and providing a keyboard response for a "go" visual target (i.e. a green rectangle), but failed to attenuate ethanol-induced reductions in inhibitory control, in response to a "no-go" target (i.e. a blue rectangle) [109,110].

Marczinski et al. [111] recently reported that the co-administration of the energy drink Red Bull® with alcohol did not alter the ethanol-induced impairment on objective measures such as dual-task information and motor coordination but reduced perceptions of mental fatigue and enhanced feelings of stimulation compared to alcohol alone. These results may suggest that the combination of ethanol with caffeine could lead to inaccurate perceptions of performance abilities [111]. This finding is particularly disturbing in light of the increased propensity to engage in alcohol-impaired driving following caffeinated alcohol intake, relative to alcohol alone [96,101], as well as findings which indicate that caffeine does not attenuate alcohol-related impairment in simulated driving or sustained attention/reaction time [112]. Overall, caffeine likely exerts stimulatory effects to counter ethanol's sedative properties, but does not alter ethanol-induced behavioral disinhibition, which could contribute to increased risk-taking during impaired driving. Similarly, Ferreira et al. [87] reported that subjective reports of physiological states and behavioral abilities following consumption of Red Bull® energy drink and 37.5% v/v vodka co-administration did not correspond to objective behavioral measures of intoxication. Participants in this study reported reduced headache, weakness, dry mouth, and motor impairment following the co-administration of an energy drink and alcohol. However, measurements of motor coordination and visual reaction time indicated no differences between individuals consuming alcohol with or without the addition of the energy drink [87].

While some behavioral data have been used to conclude that caffeinated alcohol is pharmacologically differentiable from alcohol alone, existing behavioral support for this stance is correlational. These reports could be overlooking intervening variables that link caffeinated alcoholic beverage intake with high levels of alcohol consumption, such as high sensation-seeking personality [32] or age. It also is noteworthy that many studies that report detrimental effects of mixing alcohol and caffeine were reported in the U.S. or Canada, and could reflect social or cultural norms. As indicated above, a survey of young adults in Brazil and Turkey found 75% vs. 40% engaged in caffeinated alcohol beverage consumption, respectively [87,88]. Recent reports from The Netherlands and Australia suggest that energy drink consumption actually reduces alcohol drinking [113] and/or negative alcohol-related consequences [94,113]. Thus, it currently is unclear whether caffeine's apparent exacerbation of heavy alcohol drinking reflects a physiological effect or a loading of social and demographic risk factors such as race, age, gender, culture, religion, and involvement in the college Greek community, which can influence the propensity to consume large amounts of caffeinated alcoholic beverages [86]. Regardless of whether caffeine-facilitated elevations in alcohol intake are social or biological phenomena, the long-term consequences of this behavior are cause for concern [22].

Besides the growing concern from the scientific research detailing risks associated with consumption of caffeinated alcoholic beverages reports of several deaths and hospitalizations following consumption of this drug combination have increased the focus on the potential dangers. In response to evidence that caffeinated alcohol intake may be harmful, the FDA proclaimed caffeine to be an "unsafe food additive" when combined with alcohol [22]. The primary explanation for this characterization was due to caffeine's ability to mask some indicators of alcohol intoxication, without exhibiting clear effects on alcohol metabolism [22,114]. Warning letters from the FDA to 4 caffeinated alcoholic beverage

manufacturers questioned the safety of caffeinated alcoholic beverages, and prompted several distributors to withdraw their products from the market [22]. However, it is unclear what impact this move will have on caffeinated alcohol intake in general, as reports suggest that the majority of these beverages are mixed by consumers, rather than being caffeinated prior to retail sale [89]. Further, an overall dearth in the body of research investigating the neurobehavioral effects of caffeinated alcoholic beverages weakened this warning and precluded a definitive statement regarding the relative safety of these mixtures.

Findings that alcoholics and individuals with increased vulnerability for developing AUDs also consume more caffeine confirm a need to investigate whether alcohol and caffeine co-consumption increases alcohol intake and/or increases the likelihood of developing AUDs (e.g. [97]). Young people, in particular, have exhibited an attraction for consuming caffeinated alcoholic beverages, and often engage in binge drinking this combination. An extensive literature highlights the deleterious effects, both peripherally and centrally, of binge alcohol-drinking [86]. Given that the addition of caffeine to alcoholic beverages appears to exacerbate binge-drinking, it is absolutely necessary that research into the acute and long-term effects of this combination be undertaken immediately. Following our previous findings that P rats consume more caffeine than do Wistar rats (Figure 1), as well as existing research detailing differences in ethanol intake between the two rat lines [58], our laboratory sought to examine levels of caffeinated ethanol intake in a controlled basic research environment. To that end, female P rats were assessed for intake of a caffeinated alcoholic solution, or one of its component ingredients: water, 0.3 mg/ml caffeine, or 15% ethanol over a 14-day 1-hr/day scheduled access period. In line with our a priori hypotheses, the results indicated that caffeinated ethanol intake was significantly greater than intake of water, caffeine, or ethanol alone (Figure 2). In addition, only the rats consuming caffeinated ethanol evidenced progressive increases in alcohol intake over the 14-day access period, which may signal a transition from casual drinking behaviors to dependence (data not shown). These findings may exhibit sub-additive or synergistic interactions of the two compounds, which may alter their rewarding or behavioral properties. However, without further investigation, it is unclear what neurobehavioral alterations are reflected by the increased intake of the combined compounds. In addition, these experiments were performed in female rats; however, sex-specific differences in self-administration are an important consideration. Future directions should look toward repeating these experiments in males to ascertain whether they would consume similar amounts of the solutions.

Overall, the findings indicate that caffeine elevates ethanol intake and, conversely, ethanol increases caffeine intake, even in the absence of human cultural biases. Generalized increases in activity due to the activating effects of caffeine and/or ethanol [115–119] could contribute to the increase in alcohol intake when caffeine is co-consumed. Elevations in drinking as a result of locomotor stimulation may support the common assumption that caffeine attenuates or masks the sedating effects of alcohol [91], which may enable individuals to consume more caffeinated alcohol drinks over a longer period of time [120].

Some animal research supports findings that caffeine attenuates the behavioral sedation associated with ethanol. El Yacoubi et al. [121] reported that 25 mg/kg caffeine decreased the duration of ethanol-induced loss of righting reflex in mice. Ferreira and colleagues [92]

presented evidence that caffeinated energy drinks attenuate the locomotor-depressing effects of ethanol, such that 10.71 ml/kg Red Bull® significantly decreased the sedating effects of 2.5 g/kg ethanol in Swiss mice. It is possible that combined mechanisms of caffeine and alcohol are involved in these findings. For example, caffeine can inhibit benzodiazepine binding to GABA_A receptors [122]. This is especially noteworthy/concerning because benzodiazepines are commonly used during alcohol detoxification [123], despite their high abuse/co-abuse potential [124]. These effects result primarily from caffeine blockade of adenosine receptors on striatal GABA neurons [119]. Blockade of VTA GABA_A receptor activation previously was posited to increase ethanol intake by reversing the drug's GABA-mediated sedative-hypnotic effects [125].

In line with this research, Sudakov et al. [126] reported that chronic caffeine drinking increases sensitivity to the locomotor stimulating properties of ethanol, particularly in ethanol-insensitive subjects. As motor stimulation previously has been associated with low-dose ethanol preference and reinforcement [118], this suggestion may indicate that caffeine facilitates ethanol drinking by increasing sensitivity to reward-inducing psychomotor effects associated with ethanol intake.

Pharmacokinetic Interactions of Alcohol and Caffeine

The possibility that caffeine increases alcohol intake due to changes in ethanol's pharmacokinetic properties has prompted several laboratories, including our own, to pursue this line of research. Caffeine increases metabolic rate, both in active and sedentary individuals [127]. It is plausible that the thermogenic or diuretic properties of caffeine [127–129] could facilitate ethanol elimination through increases in transdermal evaporation or water and sodium excretion. However, according to Ferreira et al. [87,92] and Kunin et al. [130], caffeine exposure does not alter ethanol pharmacokinetics in humans or rodents to a significant degree.

Ferreira et al. [87] reported that the addition of Red Bull® energy drink did not alter breath alcohol concentration levels or alcohol elimination rates associated with 0.6 or 1.0 g/kg 37.5% v/v vodka, over a 150-min time course. Similarly, intragastric administration of a Red Bull®/vodka mixture did not reduce 30-min BALs in mice [92]. Kunin et al. [130] reported similar findings using male Wistar rats. These researchers [130] reported that caffeine pretreatment (i.p.), delivered 30 min prior to systemic ethanol injections (i.p.) did not alter BALs at 15 or 30 min following alcohol exposure [130].

Our laboratory has observed similar outcomes to those presented by Kunin et al. [130] and Ferreira et al. [87,92] with regard to peak ethanol levels. We utilized subcutaneous microdialysis [131] to assess the ability of caffeine to alter alcohol pharmacokinetics in female P rats. The time-course of interstitial ethanol levels was assessed, beginning immediately after acute exposure to 1 mg/kg caffeine dissolved in 0.5 g/kg 15% w/v ethanol, or 30 mg/kg caffeine dissolved in 2.0 g/kg 15% w/v ethanol, or equivalent doses of 15% w/v ethanol alone. In line with previous evidence, we hypothesized that co-administration of caffeine would not alter the BALs of P rats. In support of this hypothesis, peak ethanol levels were not altered by caffeine co-administration. However, we did observe

some evidence that caffeine increases ethanol clearance at low doses (1 mg/kg caffeine; 0.5 g/kg ethanol; Table 1). Due to methodological differences, it is impossible to make direct comparisons with the results presented by Ferreira et al. [87], who did not observe caffeine-induced differences in ethanol clearance. Furthermore, this effect was not present with the higher dose combination, indicating that this alteration was low-dose specific. The apparent lack of effects at higher alcohol and caffeine doses does not support extrapolation of these data to explain some of the behavioral differences that have been reported following heavy consumption of caffeinated alcoholic beverages. In contrast, these data likely support previous reports that exclude differences in ethanol-related pharmacokinetics as a potential explanation for caffeine's ability to alter the effects of ethanol.

With the exception of assessing alcohol levels, few studies deliver a concentrated effort to identify the neural and physiological mechanisms that might underlie purported behavioral and cognitive differences between alcohol drinking and caffeinated alcohol drinking. To that end, research that examines neural effects of caffeine or ethanol individually often is the only available tool to extrapolate the effects of these substances when consumed in combination.

Overlapping Systems Associated with Caffeine and Ethanol: Adenosine and Dopamine

Due to the apparent behavioral and genetic interactions of AUDs and caffeine intake, an important area of research is to identify neural systems that underlie some of these interactions. Both caffeine and ethanol affect dopaminergic and adenosinergic neurotransmission, which are thought to contribute to their neurobiological and reinforcing properties. Figure 3 shows a schematic of dopamine, glutamate, and GABA neurotransmission in the MCL system, as well as providing selected evidence for the manner in which caffeine and ethanol exposure could affect these signals.

Adenosine

Adenosine is a purine neurotransmitter/neuromodulator with many (largely inhibitory) central and peripheral sites of action mediated through four identified G-protein coupled receptors, A₁, A_{2A}, A_{2B}, and A₃ [132,133]. Adenosine receptors exhibit widespread central distribution and modulate the majority of neurotransmitter systems, either directly or through indirect modulation of amino acid neurotransmitters [134,135]. Adenosine A₁- and A₃-type receptors are cyclic adenosine 5' monophosphate (cAMP)-inhibiting, while A_{2A}- and A_{2B}-type receptors are cAMP-stimulating [136]. The majority of research involving adenosine receptors has targeted the A₁ and A_{2A} receptors, which are sufficiently sensitive for activation through tonic adenosine signaling.

A₁ receptors are the most densely populated adenosine receptor subtype within the central nervous system, and are present in the hippocampus, cerebral and cerebellar cortices, hypothalamus, and some areas of the thalamus [137,138]. A₁ receptors have the highest affinity for adenosine binding (70 nM concentration) [139]. They have been associated with

physiological-behavioral functions, such as sleep, arousal, and anxiety [139]. These receptors modulate the actions of nearly all other neurotransmitters, including dopamine.

Adenosine A₂ receptors have been subdivided into A_{2A} and A_{2B} receptor types. A_{2A} receptors have an adenosine binding affinity of 150 nM. These receptors are less widespread in the CNS, relative to A₁ or A_{2B} receptors. A_{2A} receptors primarily are localized in the striatum, olfactory tubercle, nucleus accumbens (NAc), and other areas receiving significant dopamine innervation [139–141]. A₂ receptors are linked to adenylyl cyclase stimulation; their primary function is to regulate neurotransmitter release [142]. For further reviews on adenosine, see [143,144].

Adenosine and caffeine—Caffeine is a relatively nonspecific competitive antagonist of adenosine receptors. Adenosine Reports indicate that chronic caffeine exposure may reduce the compound's ability to block A₁ receptors, due to conformational changes in the receptors or endogenous ligand activity [74,145,146].

There has been a great deal of inconsistency in reports associated with the effects of caffeine intake on adenosine A_{2A} receptors. Some reports indicate that caffeine exposure does not have a lasting effect on adenosine A_{2A} receptors or their pharmacological modulators [147–149]. However, others have indicated that chronic caffeine experience up-regulates [150,151] or down-regulates [152] A_{2A} receptors. These results largely depend on the tested species and the employed caffeine exposure procedures.

Adenosine and ethanol—While the availability of research that examines caffeinated alcohol is limited, caffeine's primary pharmacological mechanism of action occurs through direct antagonism of adenosine receptors. Therefore, evidence for direct interactions of adenosine and ethanol potentially could provide useful information regarding interactions of caffeine and ethanol.

Ethanol drinking has been reported to increase A₁ receptor number [153], although chronic exposure also might desensitize these receptors in a manner similar to caffeine [74,145]. Adenosine neurotransmission has been associated with some effects of acute and prolonged ethanol exposure, as well as ethanol withdrawal [154,155]. Chronic ethanol also increases extracellular CNS adenosine levels with brain region specificity [156]. Adenosine A₁ receptors have been implicated in mediating the anxiolytic and motor impairing effects of ethanol [157,158], as well as withdrawal-induced seizures [154].

Ethanol's effects also are associated with adenosine A_{2A} receptor signaling. Adenosine A_{2A} receptors contribute to ethanol-induced motor effects. For example, El Yacoubi et al. [121] found that A_{2A} knockout mice exhibit a shorter latency to regain righting reflex following acute ethanol exposure, relative to wild-type mice. Some pre-clinical research indicates that ethanol-induced reinforcement is reduced in subjects lacking or having diminished A_{2A} receptor functioning [159,160]. It has been reported that systemic administration of 3 and 10 [159] or 10 and 20 [160] mg/kg doses of the partially selective A_{2A} receptor antagonist 3,7-dimethyl-1-propargylxanthine (DMPX) dose-dependently reduced ethanol-reinforced

operant responding. In contrast, a lower (1 mg/kg) dose of DMPX has been shown to increase ethanol-reinforced operant responding [160].

Evidence indicates that sedative and ataxic responses to ethanol also are reduced in mice lacking the equilibrative nucleoside transporter 1 [161]. This transporter is responsible for facilitating adenosine diffusion across cellular membranes. Acute ethanol exposure blocks these transporters [162–164], increasing extracellular adenosine levels, facilitating extracellular adenosine receptor activation, and inducing some of ethanol's sedative-hypnotic effects. In contrast, chronic ethanol exposure likely desensitizes these transporters to ethanol blockade and contributes to desensitization of adenosine receptors [162–164]. The widespread central effects of ethanol and caffeine are not localized to adenosine systems only. They are manifested in multiple other neural circuits, including the mesocorticolimbic (MCL) dopamine system.

Mesocorticolimbic dopamine system

The MCL dopamine system is comprised of dopamine cell bodies in the ventral tegmental area (VTA), and their projections to several forebrain areas, including the basolateral amygdala, hippocampus, lateral septum, olfactory tubercle, NAc, and the medial prefrontal cortex (mPFC). For a review on MCL dopamine activity, see [165].

Exposure to either caffeine or ethanol increases extracellular dopamine levels in MCL terminal regions [74,166–169], and stimulates feedback to the VTA to terminate dopamine output from this region [170–172]. Together, these findings suggest that caffeine and ethanol activate both inhibitory and excitatory neurocircuitry within the MCL system which may have implications for drug reward and abuse. From these and other reports, researchers have proposed that the role of adenosine receptors to modulate ethanol or caffeine reward likely is related, in part, to interactions with central dopaminergic systems.

Dopamine and adenosine in the mesocorticolimbic reward circuit—Adenosine signaling directly affects dopamine systems. Adenosine and dopamine interactions likely play integral roles in caffeine reinforcement and psychomotor stimulation. Adenosine A₁ and A_{2A} receptors are found in many dopamine-rich areas of the central nervous system, including the MCL dopamine system [162,167,168]. Research indicates that adenosine and dopamine receptors form functionally interactive, primarily antagonistic heteromeric receptor complexes [173–179]. Similarly, caffeine-induced adenosine receptor antagonism alters dopamine neurotransmission. Acute high (10 mg/kg+) caffeine doses increase extracellular NAc dopamine levels [180], while lower doses [181] or prolonged exposure [74] have no such effect (but see [167]).

Quarta et al. [74] reported that prolonged (14 day) exposure to caffeine in the drinking water results in tolerance to the ability of caffeine or an A₁ antagonist to increase extracellular NAc dopamine and glutamate levels [74]. In contrast, Borycz et al. [182] did not find that acute treatment with an A₁ receptor antagonist altered extracellular mPFC dopamine levels. In line with reports from Quarta et al. [74], chronic modulation of adenosine receptors may be necessary to observe these neuroadaptations in the A₁ receptor.

A₁ receptors likely block some of the behavioral and neurochemical actions of D₁ receptors. For example, pharmacological modulation of NAc and mPFC A₁ receptors alters motor responses to D₁ agonists and antagonists [183,184], as well as some D₁-dependent behaviors [175,183]. In line with these findings, activation of A₁ receptors desensitizes D₁ receptors in striatal and limbic regions [178,185]. Similarly, adenosine A₁ receptor blockade increases dopamine neurotransmission [145,177,186,187]. Evidence from cell lines and striatal regions indicates that A₁ receptors drive the uncoupling of dopamine D₁ receptors from stimulatory G-proteins and alter the conformation and binding affinity of MCL dopamine D₁ receptors [175,177,185,186], which could account for some of the antagonistic influence that A₁ receptors exert upon D₁ receptors. Quarta et al. [145] reported that local perfusion with A₁ receptor antagonist CPT (300 μM or 1 mM) increases extracellular NAc dopamine levels, although the range for CPT-induced alterations of dopamine neurotransmission may be concentration- and brain region-specific [182,188]. Overall, these findings suggest that A₁ receptors play an inhibitory neuromodulatory role to diminish functional kinetics associated with dopamine D₁ receptors. These effects likely represent some of the mechanisms through which adenosine receptor agonists induce sedation, and antagonists, such as caffeine, stimulate behavior [175].

Striatal A₂ receptors largely are co-expressed with postsynaptic dopamine D₂ receptors [189–191]. Research suggests that low density A₂ receptor populations are sufficient to diminish the binding affinity of dense D₂ receptor populations [192]. Constitutive populations of A₂-D₂ heteromeric complexes have been identified [173,193]. Conformational changes resulting from A₂ receptor activation are transmitted to D₂ receptors [194], and may present a mechanism through which A₂ receptor activation diminishes inhibitory D₂ receptor signaling [179]. Moreover, A_{2A} receptor antagonists decrease dopamine tissue levels [195]. Previous studies have reported that a single injection of an A₂ antagonist can decrease extracellular dopamine levels both in vivo and in vitro [145,196]. Similarly, Dassel et al. [197] reported that mutant mice with diminished striatal A₂ activity exhibit a concomitant decrease in extracellular dopamine levels, while mice lacking striatal D₂ receptors exhibit impairments in A₂ receptor-mediated functions [197]. In addition, A_{2A} receptor antagonists have been reported to counteract the cataleptic and tremor effects associated with D₂ receptor blockade [195,198]. These effects may be mediated through A_{2A} receptor antagonist-induced conformational changes in D₂ receptors and associated reductions in the binding affinity of D₂-like receptor antagonists. Ultimately, these pharmacological alterations may result in desensitization of extracellular dopamine binding to excitatory neurons and decrease dopamine-modulated behavioral pathologies [195,198]. Taken together, these findings suggest that the A₂ and D₂ receptors interact to regulate adenosine and dopamine neurotransmission, as well as their resulting behavioral outputs.

A few initiatives have examined A₁-D₂ and A_{2A}-D₁ receptor interactions. Karcz-Kubicha [199] reported that co-activation of A₁ receptors is necessary for A_{2A}-mediated increases in c-fos immunoreactivity in the mPFC anterior cingulate region [199]. These researchers [199] suggest that this permissive role for A₁ receptors is related to their ability to block tonic dopamine neurotransmission and D₂ receptor activation. A_{2A} and D₁ receptor subtypes are not largely co-localized [200]; however, there apparently are some functional and behavioral

interactions of the two receptor subtypes. For example, blockade of A₂ receptors has been reported to potentiate the excitatory neurotransmission associated with dopamine D₁ receptors [201]. In addition, A_{2A} and D₁ receptor interactions have been reported to promote alcohol consumption [202]. However, overall, evidence indicates that A₂ antagonists have greater ability to block D₂ receptor-mediated effects, relative to those modulated by D₁ receptors [193].

Dopamine and ethanol in the mesocorticolimbic reward circuit—There is substantial evidence for the involvement of the MCL dopamine system in ethanol drinking and reward. For example, neuroimaging experiments indicate that alcohol increases striatal dopamine neurotransmission in young adult males [203,204]. Similar pre-clinical findings have been reported in laboratory rodents. Pharmacologically relevant levels of ethanol have been reported to increase firing of VTA dopamine neurons [205,206]. In line with this, the VTA, NAc, and mPFC have been implicated in operant oral ethanol self-administration [207,208]. Rats will self-infuse ethanol directly into the VTA [209]. Local, peripheral and oral ethanol exposure potentiates extracellular dopamine levels in the NAc, likely leading to neuroadaptations in dopamine D₂ autoreceptor regulation of the circuit [169,210–214]. Similarly, naïve rats bred for high alcohol preference exhibit lower NAc tissue dopamine levels, compared to their alcohol non-preferring counterparts [169,215–217]. These findings suggest that differential dopamine neurotransmission in the MCL circuit could alter the reinforcing responses to ethanol exposure, and may represent a predisposing factor toward high ethanol intake and, by extension, possibly could increase the intake of caffeine, as well.

Dopamine and ethanol and adenosine in the mesocorticolimbic reward circuit—Adenosine modulation of MCL dopamine neurotransmission likely is involved in ethanol consumption. Despite the relatively low co-localization of A_{2A} and D₁ receptors [200], evidence suggests that communication between these networks may be involved in alcohol drinking. Short et al. [202] selectively deleted A_{2A} and D₁ receptors from mice to examine the involvement of these receptors in ethanol intake. Subjects with dual A_{2A} and D₁ receptor knock-out significantly reduced their ethanol intake, relative to those with single-deletion or no alteration in the receptors [218]. In contrast, Naassila et al. [219] reported that A_{2A} receptor knock-out alone increases ethanol intake (but see, [220]). Differences in these studies may suggest that dopamine D₁ receptors compensate for absent A_{2A} receptors and may implicate both of these receptor types in neural processing associated with alcohol drinking.

Yao et al. [162] found that A₂ and D₂ receptors synergize in the presence of ethanol to increase gene transcription via potentiation of PKA_{Cα} translocation to the cell nucleus. These researchers [162] reported that ethanol- and dopamine-induced increases in PKA_{Cα} translocation could be blocked by adenosine A₁ and A₂ receptor antagonists, in a manner mediated primarily by A₂ receptors [162]. This synergy likely sensitizes the system to subsequent ethanol exposure, as well as endogenous dopamine D₂ receptor signaling [162] and adenosine-mediated desensitization of G_{α_s}-coupled receptors [164]. With prolonged elevation of extracellular adenosine levels (including that associated with chronic ethanol drinking [162]), A₂ and D₂ receptors uncouple, such that the inhibitory effects of D₂

receptors predominate [221]. Chronic ethanol exposure has been reported to desensitize A_{2A} receptor response to agonists, as well as reduce the dopamine response to A_{2A} antagonism [162]. These reports present one mechanism through which A₂ receptors may alter gene expression in a D₂ receptor dependent manner. These effects may be potentiated by ethanol exposure. In line with this suggestion, Short et al. [202] reported differences in the NAc dopamine and adenosine systems of ethanol-naïve high alcohol-drinking C57Bl/6J (B6) mice and low alcohol-drinking CD-1 mice, which correlated with subsequent measures of ethanol intake. They reported decreases in D₁ receptor mRNA and increases in D₂ receptor binding in B6 vs. CD-1 mice. Short et al. [202] also reported that nucleoside transporter blocker nitrobenzylthioinosine (NBTI) binding was reduced in B6 mice, compared to the CD-1 line. This dysfunction would be expected to increase extracellular adenosine concentrations [162] and, under chronic conditions, may cause neuroadaptations, affecting adenosine receptor activity. These findings in rodent models suggest that a predisposition for high alcohol consumption may be correlated with decreases in intracellular adenosine transport.

Conclusions

The negative impact of heavy alcohol use continues to be a public health concern. Binge alcohol drinking and early onset of alcohol use, in particular, appear to be risk factors for future alcohol dependence. Existing evidence suggests that the increased availability of caffeinated alcoholic beverages exacerbates both of these predispositions for developing alcohol dependence. This underscores the need for research examining the interactions of these two substances, on cognitive, behavioral, and neuronal/physiological function. The impact of caffeinated alcohol consumption has not been characterized fully; clinical evidence is mixed regarding whether caffeine increases alcohol intake and negative alcohol-related consequences in young drinkers, relative to alcohol alone. As with most substances of abuse, the interplay between abuse and factors such as gender, age, culture, social strata and religion is complex. However, pre-clinical evidence supports the contention that caffeine increases alcohol consumption, and animal models may provide new insights into central mechanisms that underlie the rewarding and reinforcing properties of this combination. The experimental data that we have presented from our laboratory were collected in a single genetic model of heavy and binge [60] alcohol intake, the P rat, during adulthood. However, future experiments should seek to evaluate systematically whether neural and behavioral evidence associated with intake of caffeinated alcohol solutions generalizes across different genetic populations. Findings from studies using different rodent models of alcoholism (e.g. B6 mice, P rats, AA rats, sP rats, etc.) and genetic mutant animal models can be expected to reveal important information on the central effects of this often abused drug combination. Given the increasing consumption of caffeinated alcoholic beverages in high-risk populations (e.g. adolescent binge-drinkers), future research should occur at multiple developmental time-points. Knowledge of the neurocircuitry and adaptations that are associated with acute and chronic caffeinated alcohol intake, as well as their long-range alterations following such consumption, will provide useful information regarding the intervention and treatment strategies for those who abuse this combination.

Acknowledgments

The preparation of this manuscript was supported in part by AA13522, AA010717, and AA020396 from the National Institute on Alcohol Abuse and Alcoholism.

Abbreviations

MCL	Mesocorticolimbic
DA	Dopamine
VTA	Ventral Tegmental Area
mPFC	Medial Prefrontal Cortex
NAc	Nucleus Accumbens
GABA	γ -aminobutyric Acid
EtOH	Ethanol
TH	Tyrosine Hydroxylase
BDZ	Benzodiazepine
NBTI	Nitrobenzylthioinosine

References

1. NIAAA. Alcohol's Effects on the Body. 2013.
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA*. 2004; 291:1238–1245. [PubMed: 15010446]
3. Rehm J, Room R, Monteiro M, Gmel G, Graham K, et al. Alcohol as a risk factor for global burden of disease. *Eur Addict Res*. 2003; 9:157–164. [PubMed: 12970584]
4. Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ-specific endpoints of alcoholism. *Alcohol Clin Exp Res*. 1996; 20:1528–1533. [PubMed: 8986199]
5. National Highway Traffic Safety Administration. 2007 Traffic Safety Annual Assessment – Alcohol-Impaired Driving Fatalities. 2008.
6. Mercer SL, Sleet DA, Elder RW, Cole KH, Shults RA, et al. Translating evidence into policy: lessons learned from the case of lowering the legal blood alcohol limit for drivers. *Ann Epidemiol*. 2010; 20:412–420. [PubMed: 20470967]
7. McKenzie, JF.; Pinger, RR.; Koteki, JE. Alcohol, Tobacco, and Other Drugs: A Community Concern. In: Bartlett, Ja, editor. *An Introduction to Community Health*. Sudbury: 2008.
8. Brienza RS, Stein MD. Alcohol use disorders in primary care: do gender-specific differences exist? *J Gen Intern Med*. 2002; 17:387–397. [PubMed: 12047738]
9. Nelson CB, Wittchen HU. DSM-IV alcohol disorders in a general population sample of adolescents and young adults. *Addiction*. 1998; 93:1065–1077. [PubMed: 9744137]
10. Bava S, Tapert SF. Adolescent brain development and the risk for alcohol and other drug problems. *Neuropsychol Rev*. 2010; 20:398–413. [PubMed: 20953990]
11. Pitkänen T, Lyyra AL, Pulkkinen L. Age of onset of drinking and the use of alcohol in adulthood: a follow-up study from age 8–42 for females and males. *Addiction*. 2005; 100:652–661. [PubMed: 15847623]
12. Johnson PB, Glassman M. The moderating effects of gender and ethnicity on the relationship between effect expectancies and alcohol problems. *J Stud Alcohol*. 1999; 60:64–69. [PubMed: 10096310]

13. Chou SP, Pickering RP. Early onset of drinking as a risk factor for lifetime alcohol-related problems. *Br J Addict.* 1992; 87:1199–1204. [PubMed: 1511233]
14. Hawkins JD, Graham JW, Maguin E, Abbott R, Hill KG, et al. Exploring the effects of age of alcohol use initiation and psychosocial risk factors on subsequent alcohol misuse. *J Stud Alcohol.* 1997; 58:280–290. [PubMed: 9130220]
15. Dawson DA, Grant BF, Stinson FS, Chou PS. Another look at heavy episodic drinking and alcohol use disorders among college and noncollege youth. *J Stud Alcohol.* 2004; 65:477–488. [PubMed: 15378804]
16. Presley CA, Karmos JS. An instrument to assess adolescent alcohol involvement. *Addict Behav.* 1994; 19:655–665. [PubMed: 7701976]
17. Wechsler H, Kuo M, Lee H, Dowdall GW. Environmental correlates of underage alcohol use and related problems of college students. *Am J Prev Med.* 2000; 19:24–29. [PubMed: 10865160]
18. NIAAA. Underage Drinking. 2012.
19. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings. 2008.
20. Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence: age at onset, duration, and severity. *Arch Pediatr Adolesc Med.* 2006; 160:739–746. [PubMed: 16818840]
21. Martin CS, Clifford PR, Maisto SA, Earleywine M, Kirisci L, et al. Polydrug use in an inpatient treatment sample of problem drinkers. *Alcohol Clin Exp Res.* 1996; 20:413–417. [PubMed: 8727229]
22. FDA. Serious Concerns Over Alcoholic Beverages with Added Caffeine. 2010.
23. James, JE. Caffeine and Health. Academic Press; New York: 1991.
24. Gilbert RM. Caffeine consumption. *Prog Clin Biol Res.* 1984; 158:185–213. [PubMed: 6396645]
25. Griffiths, RR.; Juliano, LM.; Chausmer, A. *Addiction Medicine.* 2003. Caffeine: pharmacology and clinical effects.
26. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev.* 1999; 51:83–133. [PubMed: 10049999]
27. Dingle RN, Dreumont-Boudreau SE, Lolordo VM. Caffeine dependence in rats: effects of exposure duration and concentration. *Physiol Behav.* 2008; 95:252–257. [PubMed: 18598710]
28. Griffiths RR, Chausmer AL. Caffeine as a model drug of dependence: recent developments in understanding caffeine withdrawal, the caffeine dependence syndrome, and caffeine negative reinforcement. *Nihon Shinkei Seishin Yakurigaku Zasshi.* 2000; 20:223–231. [PubMed: 11326548]
29. Griffiths RR, Woodson PP. Reinforcing effects of caffeine in humans. *J Pharmacol Exp Ther.* 1988; 246:21–29. [PubMed: 3392652]
30. West O, Roderique-Davies G. Development and initial validation of a caffeine craving questionnaire. *J Psychopharmacol.* 2008; 22:80–91. [PubMed: 18187535]
31. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders.* 4. Washington, DC: 2004. text rev
32. Jones HA, Lejuez CW. Personality correlates of caffeine dependence: the role of sensation seeking, impulsivity, and risk taking. *Exp Clin Psychopharmacol.* 2005; 13:259–266. [PubMed: 16173890]
33. Ogawa N, Ueki H. Clinical importance of caffeine dependence and abuse. *Psychiatry Clin Neurosci.* 2007; 61:263–268. [PubMed: 17472594]
34. Bernstein GA, Carroll ME, Thuras PD, Cosgrove KP, Roth ME. Caffeine dependence in teenagers. *Drug Alcohol Depend.* 2002; 66:1–6. [PubMed: 11850129]
35. Oberstar JV, Bernstein GA, Thuras PD. Caffeine use and dependence in adolescents: one-year follow-up. *J Child Adolesc Psychopharmacol.* 2002; 12:127–135. [PubMed: 12188981]
36. Young C, Oladipo O, Frasier S, Putko R, Chronister S, et al. Hemorrhagic stroke in young healthy male following use of sports supplement Jack3d. *Mil Med.* 2012; 177:1450–1454. [PubMed: 23397687]
37. Kendler KS, Prescott CA. Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. *Am J Psychiatry.* 1999; 156:223–228. [PubMed: 9989558]

38. Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. *Arch Gen Psychiatry*. 2003; 60:929–937. [PubMed: 12963675]
39. Bierut LJ, Dinwiddie SH, Begleiter H, Crowe RR, Hesselbrock V, et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. *Arch Gen Psychiatry*. 1998; 55:982–988. [PubMed: 9819066]
40. Goldman D, Bergen A. General and specific inheritance of substance abuse and alcoholism. *Arch Gen Psychiatry*. 1998; 55:964–965. [PubMed: 9819063]
41. Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. *Arch Gen Psychiatry*. 1998; 55:967–972. [PubMed: 9819064]
42. Swan GE, Carmelli D, Cardon LR. The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. *J Subst Abuse*. 1996; 8:19–31. [PubMed: 8743766]
43. Zeiner AR, Stanitis T, Spurgeon M, Nichols N. Treatment of alcoholism and concomitant drugs of abuse. *Alcohol*. 1985; 2:555–559. [PubMed: 4026979]
44. Aubin HJ, Laureaux C, Tilikete S, Barrucand D. Changes in cigarette smoking and coffee drinking after alcohol detoxification in alcoholics. *Addiction*. 1999; 94:411–416. [PubMed: 10605869]
45. Kendler KS, Aggen SH, Prescott CA, Crabbe J, Neale MC. Evidence for multiple genetic factors underlying the DSM-IV criteria for alcohol dependence. *Mol Psychiatry*. 2012; 17:1306–1315. [PubMed: 22105626]
46. Kendler KS, Sundquist K, Ohlsson H, Palmér K, Maes H, et al. Genetic and familial environmental influences on the risk for drug abuse: a national Swedish adoption study. *Arch Gen Psychiatry*. 2012; 69:690–697. [PubMed: 22393206]
47. Bevilacqua L, Goldman D. Genes and addictions. *Clin Pharmacol Ther*. 2009; 85:359–361. [PubMed: 19295534]
48. Hughes JR, Oliveto AH, MacLaughlin M. Is dependence on one drug associated with dependence on other drugs? The cases of alcohol, caffeine and nicotine. *Am J Addict*. 2000; 9:196–201. [PubMed: 11000915]
49. Strain EC, Mumford GK, Silverman K, Griffiths RR. Caffeine dependence syndrome. Evidence from case histories and experimental evaluations. *JAMA*. 1994; 272:1043–1048. [PubMed: 8089887]
50. Istvan J, Matarazzo JD. Tobacco, alcohol, and caffeine use: a review of their interrelationships. *Psychol Bull*. 1984; 95:301–326. [PubMed: 6544436]
51. Svikis DS, Berger N, Haug NA, Griffiths RR. Caffeine dependence in combination with a family history of alcoholism as a predictor of continued use of caffeine during pregnancy. *Am J Psychiatry*. 2005; 162:2344–2351. [PubMed: 16330600]
52. Bergin JE, Kendler KS. Common psychiatric disorders and caffeine use, tolerance, and withdrawal: an examination of shared genetic and environmental effects. *Twin Res Hum Genet*. 2012; 15:473–482. [PubMed: 22854069]
53. Lester D, Freed EX. Criteria for an animal model of alcoholism. *Pharmacol Biochem Behav*. 1973; 1:103–107. [PubMed: 4204511]
54. McBride WJ, Li TK. Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. *Crit Rev Neurobiol*. 1998; 12:339–369. [PubMed: 10348615]
55. Crabbe JC, Phillips TJ, Belknap JK. The complexity of alcohol drinking: studies in rodent genetic models. *Behav Genet*. 2010; 40:737–750. [PubMed: 20552264]
56. Bell RL, Sable HJ, Colombo G, Hyytia P, Rodd ZA, Lumeng L. Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity. *Pharmacol Biochem Behav*. 2012; 103:119–155. [PubMed: 22841890]
57. Bell RL, Rodd ZA, Lumeng L, Murphy JM, McBride WJ. The alcohol-preferring P rat and animal models of excessive alcohol drinking. *Addict Biol*. 2006; 11:270–288. [PubMed: 16961759]
58. Murphy JM, Stewart RB, Bell RL, Badia-Elder NE, Carr LG, et al. Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference. *Behav Genet*. 2002; 32:363–388. [PubMed: 12405517]

59. Bell RL, Kimpel MW, Rodd ZA, Strother WN, Bai F, et al. Protein expression changes in the nucleus accumbens and amygdala of inbred alcohol-preferring rats given either continuous or scheduled access to ethanol. *Alcohol*. 2006; 40:3–17. [PubMed: 17157716]
60. Bell RL, Rodd ZA, Smith RJ, Toalston JE, Franklin KM, et al. Modeling binge-like ethanol drinking by peri-adolescent and adult P rats. *Pharmacol Biochem Behav*. 2011; 100:90–97. [PubMed: 21824488]
61. Dhaher R, McConnell KK, Rodd ZA, McBride WJ, Bell RL. Daily patterns of ethanol drinking in adolescent and adult, male and female, high alcohol drinking (HAD) replicate lines of rats. *Pharmacol Biochem Behav*. 2012; 102:540–548. [PubMed: 22750062]
62. Bell RL, Rodd-Henricks ZA, Webster AA, Lumeng L, Li TK, et al. Heart rate and motor-activating effects of orally self-administered ethanol in alcohol-preferring (P) rats. *Alcohol Clin Exp Res*. 2002; 26:1162–1170. [PubMed: 12198390]
63. Bell RL, Rodd ZA, Sable HJ, Schultz JA, Hsu CC, et al. Daily patterns of ethanol drinking in peri-adolescent and adult alcohol-preferring (P) rats. *Pharmacol Biochem Behav*. 2006; 83:35–46. [PubMed: 16442608]
64. Gordon TL, Meehan SM, Schechter MD. P and NP rats respond differently to the discriminative stimulus effects of nicotine. *Pharmacol Biochem Behav*. 1993; 45:305–308. [PubMed: 8327536]
65. Meehan SM, Gordon TL, Schechter MD. MDMA (Ecstasy) substitutes for the ethanol discriminative cue in HAD but not LAD rats. *Alcohol*. 1995; 12:569–572. [PubMed: 8590621]
66. Katner SN, Oster SM, Ding ZM, Deehan GA Jr, Toalston JE, et al. Alcohol-preferring (P) rats are more sensitive than Wistar rats to the reinforcing effects of cocaine self-administered directly into the nucleus accumbens shell. *Pharmacol Biochem Behav*. 2011; 99:688–695. [PubMed: 21723879]
67. Eiler WJ 2nd, Woods JE 2nd, Masters J, McKay PF, Hardy L 3rd, et al. Brain stimulation reward performance and sucrose maintained behaviors in alcohol-preferring and -nonpreferring rats. *Alcohol Clin Exp Res*. 2005; 29:571–583. [PubMed: 15834222]
68. Nowak KL, Ingraham CM, Mckinzie DL, McBride WJ, Lumeng L, et al. An assessment of novelty-seeking behavior in alcohol-preferring and nonpreferring rats. *Pharmacol Biochem Behav*. 2000; 66:113–121. [PubMed: 10837850]
69. Hyytiä P, Sinclair JD. Oral etonitazene and cocaine consumption by AA, ANA and Wistar rats. *Psychopharmacology (Berl)*. 1993; 111:409–414. [PubMed: 7870981]
70. Stromberg MF, Mackler SA. The effect of cocaine on the expression of motor activity and conditioned place preference in high and low alcohol-preferring Wistar rats. *Pharmacol Biochem Behav*. 2005; 82:314–319. [PubMed: 16199082]
71. Marttila K, Petteri Piepponen T, Kiiianmaa K, Ahtee L. Accumbal FosB/DeltaFosB immunoreactivity and conditioned place preference in alcohol-preferring AA rats and alcohol-avoiding ANA rats treated repeatedly with cocaine. *Brain Res*. 2007; 1160:82–90. [PubMed: 17572394]
72. Leggio B, Masi F, Grappi S, Nanni G, Gambarana C, et al. Sardinian alcohol-preferring and non-preferring rats show different reactivity to aversive stimuli and a similar response to a natural reward. *Brain Res*. 2003; 973:275–284. [PubMed: 12738071]
73. Mikkola JA, Honkanen A, Piepponen TP, Kiiianmaa K, Ahtee L. Effects of repeated cocaine treatment on striatal dopamine release in alcohol-preferring AA and alcohol-avoiding ANA rats. *Naunyn Schmiedebergs Arch Pharmacol*. 2001; 363:209–214. [PubMed: 11218073]
74. Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, et al. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. *J Neurochem*. 2004; 91:873–880. [PubMed: 15525341]
75. Mayo Clinic. Caffeine content for coffee, tea, soda and more. 2012.
76. Vitiello MV, Woods SC. Caffeine: preferential consumption by rats. *Pharmacol Biochem Behav*. 1975; 3:147–149. [PubMed: 1170574]
77. Bell RL, Stewart RB, Woods JE 2nd, Lumeng L, Li TK, et al. Responsivity and development of tolerance to the motor impairing effects of moderate doses of ethanol in alcohol-preferring (P) and -nonpreferring (NP) rat lines. *Alcohol Clin Exp Res*. 2001; 25:644–650. [PubMed: 11371712]

78. Reissig CJ, Strain EC, Griffiths RR. Caffeinated energy drinks--a growing problem. *Drug Alcohol Depend.* 2009; 99:1–10. [PubMed: 18809264]
79. The Coca-Cola Company.
80. PepsiCo Inc. 2011
81. The Mintel Group Ltd. *Energy Drinks.* 2007.
82. The Mintel Group. *Energy Drinks and Energy Shots.* 2009.
83. Centers for Disease Control. *Binge Drinking.* 2012.
84. Marczynski CA. Alcohol mixed with energy drinks: consumption patterns and motivations for use in U.S. college students. *Int J Environ Res Public Health.* 2011; 8:3232–3245. [PubMed: 21909303]
85. Mart SM. Alcohol marketing in the 21st century: new methods, old problems. *Subst Use Misuse.* 2011; 46:889–892. [PubMed: 21599504]
86. O'Brien MC, McCoy TP, Rhodes SD, Wagoner A, Wolfson M. Caffeinated cocktails: energy drink consumption, high-risk drinking, and alcohol-related consequences among college students. *Acad Emerg Med.* 2008; 15:453–460. [PubMed: 18439201]
87. Ferreira SE, de Mello MT, Pompéia S, de Souza-Formigoni ML. Effects of energy drink ingestion on alcohol intoxication. *Alcohol Clin Exp Res.* 2006; 30:598–605. [PubMed: 16573577]
88. Attila S, Çakir B. Energy-drink consumption in college students and associated factors. *Nutrition.* 2011; 27:316–322. [PubMed: 20579846]
89. MacKillop J, Howland J, Rohsenow DJ, Few LR, Amlung MT, et al. Initial development of a measure of expectancies for combinations of alcohol and caffeine: the Caffeine + Alcohol Combined Effects Questionnaire (CACEQ). *Exp Clin Psychopharmacol.* 2012; 20:466–472. [PubMed: 23230858]
90. Smith AP. Effects of caffeine and alcohol on mood and performance changes following consumption of lager. *Psychopharmacology (Berl).* 2013; 227:595–604. [PubMed: 23377024]
91. Marczynski CA, Fillmore MT. Clubgoers and their trendy cocktails: implications of mixing caffeine into alcohol on information processing and subjective reports of intoxication. *Exp Clin Psychopharmacol.* 2006; 14:450–458. [PubMed: 17115872]
92. Ferreira SE, Hartmann Quadros IM, Trindade AA, Takahashi S, Koyama RG, et al. Can energy drinks reduce the depressor effect of ethanol? An experimental study in mice. *Physiol Behav.* 2004; 82:841–847. [PubMed: 15451648]
93. Alford C, Hamilton-Morris J, Verster JC. The effects of energy drink in combination with alcohol on performance and subjective awareness. *Psychopharmacology (Berl).* 2012; 222:519–532. [PubMed: 22456862]
94. Peacock A, Bruno R, Martin FH. The subjective physiological, psychological, and behavioral risk-taking consequences of alcohol and energy drink co-ingestion. *Alcohol Clin Exp Res.* 2012; 36:2008–2015. [PubMed: 22897756]
95. Peacock A, Bruno R, Martin FH. Patterns of use and motivations for consuming alcohol mixed with energy drinks. *Psychol Addict Behav.* 2013; 27:202–206. [PubMed: 22985055]
96. Thombs D, Rossheim M, Barnett TE, Weiler RM, Moorhouse MD, et al. Is there a misplaced focus on AmED? Associations between caffeine mixers and bar patron intoxication. *Drug Alcohol Depend.* 2011; 116:31–36. [PubMed: 21177047]
97. Arria AM, Caldeira KM, Kasperski SJ, Vincent KB, Griffiths RR, et al. Energy drink consumption and increased risk for alcohol dependence. *Alcohol Clin Exp Res.* 2011; 35:365–375. [PubMed: 21073486]
98. Skeen MP, Glenn LL. Imaginary link between alcoholism and energy drinks. *Alcohol Clin Exp Res.* 2011; 35:1375–1376. [PubMed: 21651587]
99. Brache K, Stockwell T. Drinking patterns and risk behaviors associated with combined alcohol and energy drink consumption in college drinkers. *Addict Behav.* 2011; 36:1133–1140. [PubMed: 21840130]
100. Riesselmann B, Rosenbaum F, Schneider V. Alcohol and energy drink--can combined consumption of both beverages modify automobile driving fitness? *Blutalkohol.* 1996; 33:201–208. [PubMed: 8924273]

101. Thombs DL, O'Mara RJ, Tsukamoto M, Rossheim ME, Weiler RM, et al. Event-level analyses of energy drink consumption and alcohol intoxication in bar patrons. *Addict Behav.* 2010; 35:325–330. [PubMed: 19954894]
102. Wolk BJ, Ganetsky M, Babu KM. Toxicity of energy drinks. *Curr Opin Pediatr.* 2012; 24:243–251. [PubMed: 22426157]
103. Weldy DL. Risks of alcoholic energy drinks for youth. *J Am Board Fam Med.* 2010; 23:555–558. [PubMed: 20616299]
104. Curry K, Stasio MJ. The effects of energy drinks alone and with alcohol on neuropsychological functioning. *Hum Psychopharmacol.* 2009; 24:473–481. [PubMed: 19606453]
105. Mackay M, Tiplady B, Scholey AB. Interactions between alcohol and caffeine in relation to psychomotor speed and accuracy. *Hum Psychopharmacol.* 2002; 17:151–156. [PubMed: 12404692]
106. Grattan-Miscio KE, Vogel-Sprott M. Alcohol, intentional control, and inappropriate behavior: regulation by caffeine or an incentive. *Exp Clin Psychopharmacol.* 2005; 13:48–55. [PubMed: 15727503]
107. Fillmore MT, Roach EL, Rice JT. Does caffeine counteract alcohol-induced impairment? The ironic effects of expectancy. *J Stud Alcohol.* 2002; 63:745–754. [PubMed: 12529075]
108. Fillmore MT. Alcohol tolerance in humans is enhanced by prior caffeine antagonism of alcohol-induced impairment. *Exp Clin Psychopharmacol.* 2003; 11:9–17. [PubMed: 12622339]
109. Marczynski CA, Fillmore MT. Dissociative antagonistic effects of caffeine on alcohol-induced impairment of behavioral control. *Exp Clin Psychopharmacol.* 2003; 11:228–236. [PubMed: 12940502]
110. Marczynski CA, Fillmore MT, Bardgett ME, Howard MA. Effects of energy drinks mixed with alcohol on behavioral control: risks for college students consuming trendy cocktails. *Alcohol Clin Exp Res.* 2011; 35:1282–1292. [PubMed: 21676002]
111. Marczynski CA, Fillmore MT, Henges AL, Ramsey MA, Young CR. Effects of energy drinks mixed with alcohol on information processing, motor coordination and subjective reports of intoxication. *Exp Clin Psychopharmacol.* 2012; 20:129–138. [PubMed: 22023670]
112. Howland J, Rohsenow DJ, Arnedt JT, Bliss CA, Hunt SK, et al. The acute effects of caffeinated versus non-caffeinated alcoholic beverage on driving performance and attention/reaction time. *Addiction.* 2011; 106:335–341. [PubMed: 21134017]
113. de Haan L, de Haan HA, van der Palen J, Olivier B, Verster JC. Effects of consuming alcohol mixed with energy drinks versus consuming alcohol only on overall alcohol consumption and negative alcohol-related consequences. *Int J Gen Med.* 2012; 5:953–960. [PubMed: 23204859]
114. Benac N. United States Food and Drug Administration signals crackdown on caffeinated alcohol drinks. *CMAJ.* 2011; 183:E47–48. [PubMed: 21149520]
115. Hsu CW, Chen CY, Wang CS, Chiu TH. Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice. *Psychopharmacology (Berl).* 2009; 204:313–325. [PubMed: 19169672]
116. Agabio R, Carai MA, Lobina C, Pani M, Reali R, et al. Alcohol stimulates motor activity in selectively bred Sardinian alcohol-preferring (sP), but not in Sardinian alcohol-nonpreferring (sNP), rats. *Alcohol.* 2001; 23:123–126. [PubMed: 11331110]
117. El Yacoubi M, Ledent C, Ménard JF, Parmentier M, Costentin J, et al. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. *Br J Pharmacol.* 2000; 129:1465–1473. [PubMed: 10742303]
118. Waller MB, Murphy JM, McBride WJ, Lumeng L, Li TK. Effect of low dose ethanol on spontaneous motor activity in alcohol-preferring and -nonpreferring lines of rats. *Pharmacol Biochem Behav.* 1986; 24:617–623. [PubMed: 3703897]
119. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. *Cell Mol Life Sci.* 2004; 61:857–872. [PubMed: 15095008]
120. Howland J, Rohsenow DJ, Greece JA, Littlefield CA, Almeida A, et al. The effects of binge drinking on college students' next-day academic test-taking performance and mood state. *Addiction.* 2010; 105:655–665. [PubMed: 20403018]

121. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade. *Neuropharmacology*. 2003; 45:977–985. [PubMed: 14573390]
122. Marangos PJ, Paul SM, Parma AM, Goodwin FK, Syapin P, et al. Purinergic inhibition of diazepam binding to rat brain (in vitro). *Life Sci*. 1979; 24:851–857. [PubMed: 449624]
123. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. *Cochrane Database Syst Rev*. 2010:CD005063. [PubMed: 20238336]
124. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse. *Psychopharmacology (Berl)*. 1997; 134:1–37. [PubMed: 9399364]
125. Nowak KL, McBride WJ, Lumeng L, Li TK, Murphy JM. Blocking GABA(A) receptors in the anterior ventral tegmental area attenuates ethanol intake of the alcohol-preferring P rat. *Psychopharmacology (Berl)*. 1998; 139:108–116. [PubMed: 9768548]
126. Sudakov SK, Rusakova IV, Medvedeva OF. Effect of chronic caffeine consumption on changes in locomotor activity of WAG/G and Fischer-344 rats induced by nicotine, ethanol, and morphine. *Bull Exp Biol Med*. 2003; 136:563–565. [PubMed: 15500072]
127. Armstrong LE. Caffeine, body fluid-electrolyte balance, and exercise performance. *Int J Sport Nutr Exerc Metab*. 2002; 12:189–206. [PubMed: 12187618]
128. Belza A, Toubro S, Astrup A. The effect of caffeine, green tea and tyrosine on thermogenesis and energy intake. *Eur J Clin Nutr*. 2009; 63:57–64. [PubMed: 17882140]
129. Riesenhuber A, Boehm M, Posch M, Aufrecht C. Diuretic potential of energy drinks. *Amino Acids*. 2006; 31:81–83. [PubMed: 16847703]
130. Kunin D, Gaskin S, Rogan F, Smith BR, Amit Z. Caffeine promotes ethanol drinking in rats. Examination using a limited-access free choice paradigm. *Alcohol*. 2000; 21:271–277. [PubMed: 11091031]
131. Engleman EA, Ingraham CM, Franklin KM, Keith CM, McClaren JA, et al. In vivo time-course changes in ethanol levels sampled with subcutaneous microdialysis. *Alcohol Clin Exp Res*. 2008; 32:435–442. [PubMed: 18215218]
132. Williams M, Jarvis MF. Purinergic and pyrimidinergic receptors as potential drug targets. *Biochem Pharmacol*. 2000; 59:1173–1185. [PubMed: 10736418]
133. Dunwiddie TV. The physiological role of adenosine in the central nervous system. *Int Rev Neurobiol*. 1985; 27:63–139. [PubMed: 2867982]
134. Martín R, Ladera C, Bartolomé-Martín D, Torres M, Sánchez-Prieto J. The inhibition of release by mGlu7 receptors is independent of the Ca²⁺ channel type but associated to GABAB and adenosine A1 receptors. *Neuropharmacology*. 2008; 55:464–473. [PubMed: 18514236]
135. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S. Adenosine A2A receptors and basal ganglia physiology. *Prog Neurobiol*. 2007; 83:277–292. [PubMed: 17646043]
136. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. *Annu Rev Pharmacol Toxicol*. 1995; 35:581–606. [PubMed: 7598508]
137. Fastbom J, Pazos A, Palacios JM. The distribution of adenosine A1 receptors and 5'-nucleotidase in the brain of some commonly used experimental animals. *Neuroscience*. 1987; 22:813–826. [PubMed: 2825070]
138. Rivkees SA, Lasbury ME, Stiles GS, Henegariu O, Curtis C, et al. The human A1 adenosine receptor: ligand binding properties, sites of somatic expression and chromosomal localization. *Endocrine*. 1995; 3:623–629. [PubMed: 21153220]
139. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci*. 2001; 24:31–55. [PubMed: 11283304]
140. Parkinson FE, Fredholm BB. Autoradiographic evidence for G-protein coupled A2-receptors in rat neostriatum using [3H]-CGS 21680 as a ligand. *Naunyn Schmiedebergs Arch Pharmacol*. 1990; 342:85–89. [PubMed: 1698265]
141. Wan W, Sutherland GR, Geiger JD. Binding of the adenosine A2 receptor ligand [3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. *J Neurochem*. 1990; 55:1763–1771. [PubMed: 2213023]

142. GoÅ, embiowska K, Zylewska A. Adenosine receptors--the role in modulation of dopamine and glutamate release in the rat striatum. *Pol J Pharmacol.* 1997; 49:317–322. [PubMed: 9566030]
143. Burnstock G. Introduction to purinergic signalling in the brain. *Adv Exp Med Biol.* 2013; 986:1–12. [PubMed: 22879061]
144. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets--what are the challenges? *Nat Rev Drug Discov.* 2013; 12:265–286. [PubMed: 23535933]
145. Quarta D, Ferre S, Solinas M, You ZB, Hockemeyer J, et al. Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. *J Neurochem.* 2004; 88:1151–1158. [PubMed: 15009670]
146. Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, et al. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. *Neuropsychopharmacology.* 2003; 28:1281–1291. [PubMed: 12700682]
147. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, et al. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. *J Clin Pharmacol.* 1997; 37:693–703. [PubMed: 9378841]
148. Shi D, Nikodijevi O, Jacobson KA, Daly JW. Effects of chronic caffeine on adenosine, dopamine and acetylcholine systems in mice. *Arch Int Pharmacodyn Ther.* 1994; 328:261–287. [PubMed: 7625882]
149. Popoli P, Reggio R, Pèzzola A. Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake. *Neuropsychopharmacology.* 2000; 22:522–529. [PubMed: 10731627]
150. Traversa U, Rosati AM, Florio C, Vertua R. Effects of chronic administration of adenosine antagonists on adenosine A1 and A2a receptors in mouse brain. *In Vivo.* 1994; 8:1073–1078. [PubMed: 7772740]
151. Hawkins M, Dugich MM, Porter NM, Urbancic M, Radulovacki M. Effects of chronic administration of caffeine on adenosine A1 and A2 receptors in rat brain. *Brain Res Bull.* 1988; 21:479–482. [PubMed: 3214753]
152. Svenningsson P, Nomikos GG, Fredholm BB. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. *J Neurosci.* 1999; 19:4011–4022. [PubMed: 10234030]
153. Daly JW, Shi D, Wong V, Nikodijevic O. Chronic effects of ethanol on central adenosine function of mice. *Brain Res.* 1994; 650:153–156. [PubMed: 7953667]
154. Jarvis MF, Becker HC. Single and repeated episodes of ethanol withdrawal increase adenosine A1, but not A2A, receptor density in mouse brain. *Brain Res.* 1998; 786:80–88. [PubMed: 9554962]
155. Butler TR, Prendergast MA. Neuroadaptations in adenosine receptor signaling following long-term ethanol exposure and withdrawal. *Alcohol Clin Exp Res.* 2012; 36:4–13. [PubMed: 21762181]
156. Sharma R, Engemann SC, Sahota P, Thakkar MM. Effects of ethanol on extracellular levels of adenosine in the basal forebrain: an in vivo microdialysis study in freely behaving rats. *Alcohol Clin Exp Res.* 2010; 34:813–818. [PubMed: 20184564]
157. Batista LC, Prediger RD, Morato GS, Takahashi RN. Blockade of adenosine and dopamine receptors inhibits the development of rapid tolerance to ethanol in mice. *Psychopharmacology (Berl).* 2005; 181:714–721. [PubMed: 15983797]
158. Prediger RD, Batista LC, Takahashi RN. Adenosine A1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice. *Eur J Pharmacol.* 2004; 499:147–154. [PubMed: 15363961]
159. Thorsell A, Johnson J, Heilig M. Effect of the adenosine A2a receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats. *Alcohol Clin Exp Res.* 2007; 31:1302–1307. [PubMed: 17550371]
160. Arolfo MP, Yao L, Gordon AS, Diamond I, Janak PH. Ethanol operant self-administration in rats is regulated by adenosine A2 receptors. *Alcohol Clin Exp Res.* 2004; 28:1308–1316. [PubMed: 15365300]

161. Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. *Nat Neurosci.* 2004; 7:855–861. [PubMed: 15258586]
162. Yao L, Arolfo MP, Dohrman DP, Jiang Z, Fan P, et al. betagamma Dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. *Cell.* 2002; 109:733–743. [PubMed: 12086672]
163. Sapru MK, Diamond I, Gordon AS. Adenosine receptors mediate cellular adaptation to ethanol in NG108–15 cells. *J Pharmacol Exp Ther.* 1994; 271:542–548. [PubMed: 7965754]
164. Nagy LE, Diamond I, Collier K, Lopez L, Ullman B, et al. Adenosine is required for ethanol-induced heterologous desensitization. *Mol Pharmacol.* 1989; 36:744–748. [PubMed: 2555672]
165. Van den Heuvel DM, Pasterkamp RJ. Getting connected in the dopamine system. *Prog Neurobiol.* 2008; 85:75–93. [PubMed: 18304718]
166. Tu Y, Kroener S, Abernathy K, Lapish C, Seamans J, et al. Ethanol inhibits persistent activity in prefrontal cortical neurons. *J Neurosci.* 2007; 27:4765–4775. [PubMed: 17460089]
167. De Luca MA, Bassareo V, Bauer A, Di Chiara G. Caffeine and accumbens shell dopamine. *J Neurochem.* 2007; 103:157–163. [PubMed: 17655660]
168. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. *Neuropsychopharmacology.* 2002; 27:182–193. [PubMed: 12093592]
169. Smith AD, Weiss F. Ethanol exposure differentially alters central monoamine neurotransmission in alcohol-preferring versus -nonpreferring rats. *J Pharmacol Exp Ther.* 1999; 288:1223–1228. [PubMed: 10027862]
170. Rahman S, McBride WJ. D1-D2 dopamine receptor interaction within the nucleus accumbens mediates long-loop negative feedback to the ventral tegmental area (VTA). *J Neurochem.* 2001; 77:1248–1255. [PubMed: 11389175]
171. Kohl RR, Katner JS, Chernet E, McBride WJ. Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. *Psychopharmacology (Berl).* 1998; 139:79–85. [PubMed: 9768545]
172. Stoner GR, Skirboll LR, Werkman S, Hommer DW. Preferential effects of caffeine on limbic and cortical dopamine systems. *Biol Psychiatry.* 1988; 23:761–768. [PubMed: 2835113]
173. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J Biol Chem.* 2003; 278:46741–46749. [PubMed: 12933819]
174. Ginés S, Hillion J, Torvinen M, Le Crom S, Casadó V, et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. *Proc Natl Acad Sci U S A.* 2000; 97:8606–8611. [PubMed: 10890919]
175. Ferré S, Popoli P, Giménez-Llort L, Finnman UB, Martínez E, et al. Postsynaptic antagonistic interaction between adenosine A1 and dopamine D1 receptors. *Neuroreport.* 1994; 6:73–76. [PubMed: 7703433]
176. Ferré S, O'Connor WT, Snaprud P, Ungerstedt U, Fuxe K. Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. *Neuroscience.* 1994; 63:765–773. [PubMed: 7898676]
177. Ferré S, Torvinen M, Antoniou K, Irenius E, Civelli O, et al. Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells. *J Biol Chem.* 1998; 273:4718–4724. [PubMed: 9468534]
178. O'Neill C, Nolan BJ, Macari A, O'Boyle KM, O'Connor JJ. Adenosine A1 receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors. *Eur J Neurosci.* 2007; 26:3421–3428. [PubMed: 18052983]
179. Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. *Physiol Behav.* 2007; 92:210–217. [PubMed: 17572452]

180. Nehlig A, Daval JL, Boyet S, Vert P. Comparative effects of acute and chronic administration of caffeine on local cerebral glucose utilization in the conscious rat. *Eur J Pharmacol.* 1986; 129:93–103. [PubMed: 3770076]
181. Nehlig A, Boyet S. Dose-response study of caffeine effects on cerebral functional activity with a specific focus on dependence. *Brain Res.* 2000; 858:71–77. [PubMed: 10700599]
182. Borycz J, Pereira MF, Melani A, Rodrigues RJ, Kofalvi A, et al. Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. *J Neurochem.* 2007; 101:355–363. [PubMed: 17254024]
183. Rimondini R, Ferré S, Giménez-Llort L, Ogren SO, Fuxe K. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. *Eur J Pharmacol.* 1998; 347:153–158. [PubMed: 9653875]
184. Popoli P, Giménez-Llort L, Pezzola A, Reggio R, Martínez E, et al. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. *Neurosci Lett.* 1996; 218:209–213. [PubMed: 8945765]
185. Ferre S, Popoli P, Tinner-Staines B, Fuxe K. Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. *Neurosci Lett.* 1996; 208:109–112. [PubMed: 8859902]
186. Cao Y, Xie KQ, Zhu XZ. The enhancement of dopamine D1 receptor desensitization by adenosine A1 receptor activation. *Eur J Pharmacol.* 2007; 562:34–38. [PubMed: 17368618]
187. Okada M, Mizuno K, Kaneko S. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. *Neurosci Lett.* 1996; 212:53–56. [PubMed: 8823761]
188. Zetterström T, Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. *Eur J Pharmacol.* 1990; 180:137–143. [PubMed: 2364998]
189. Ferré S, Ciruela F, Quiroz C, Luján R, Popoli P, et al. Adenosine receptor heteromers and their integrative role in striatal function. *ScientificWorldJournal.* 2007; 7:74–85. [PubMed: 17982579]
190. Leonard SK, Ferry-Leeper P, Mailman RB. Low affinity binding of the classical D1 antagonist SCH23390 in rodent brain: potential interaction with A2A and D2-like receptors. *Brain Res.* 2006; 1117:25–37. [PubMed: 16962565]
191. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A) R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. *Proc Natl Acad Sci U S A.* 2001; 98:1970–1975. [PubMed: 11172060]
192. Torvinen M, Marcellino D, Canals M, Agnati LF, Lluís C, et al. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. *Mol Pharmacol.* 2005; 67:400–407. [PubMed: 15539641]
193. Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, et al. The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. *Psychopharmacology (Berl).* 2009; 203:489–499. [PubMed: 19048234]
194. Agnati LF, Ferre S, Lluís C, Franco R, Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. *Pharmacol Rev.* 2003; 55:509–550. [PubMed: 12869660]
195. Luthra PM, Prakash A, Barodia SK, Kumari R, Mishra CB, et al. In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice. *Neurosci Lett.* 2009; 463:215–218. [PubMed: 19654038]
196. Koizumi S, Watano T, Nakazawa K, Inoue K. Potentiation by adenosine of ATP-evoked dopamine release via a pertussis toxin-sensitive mechanism in rat phaeochromocytoma PC12 cells. *Br J Pharmacol.* 1994; 112:992–997. [PubMed: 7921629]
197. Dasselme D, Massie A, Ferrari R, Ledent C, Parmentier M, et al. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. *J Neurochem.* 2001; 78:183–198. [PubMed: 11432985]
198. Ishiwari K, Madson LJ, Farrar AM, Mingote SM, Valenta JP, et al. Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor

- suppression induced by haloperidol in rats. *Behav Brain Res.* 2007; 178:190–199. [PubMed: 17223207]
199. Karcz-Kubicha M, Quarta D, Hope BT, Antoniou K, Müller CE, et al. Enabling role of adenosine A1 receptors in adenosine A2A receptor-mediated striatal expression of c-fos. *Eur J Neurosci.* 2003; 18:296–302. [PubMed: 12887411]
 200. Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, et al. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. *Neuroscience.* 1997; 80:1171–1185. [PubMed: 9284069]
 201. Cauli O, Morelli M. Caffeine and the dopaminergic system. *Behav Pharmacol.* 2005; 16:63–77. [PubMed: 15767841]
 202. Short JL, Ledent C, Drago J, Lawrence AJ. Receptor crosstalk: characterization of mice deficient in dopamine D1 and adenosine A2A receptors. *Neuropsychopharmacology.* 2006; 31:525–534. [PubMed: 16123762]
 203. Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, et al. Alcohol promotes dopamine release in the human nucleus accumbens. *Synapse.* 2003; 49:226–231. [PubMed: 12827641]
 204. Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, et al. Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride. *Biol Psychiatry.* 2010; 68:689–696. [PubMed: 20678752]
 205. Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. *Brain Res.* 1990; 508:65–69. [PubMed: 2337793]
 206. Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. *Brain Res.* 1985; 348:201–203. [PubMed: 2998561]
 207. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. *J Neurosci.* 1998; 18:10663–10671. [PubMed: 9852601]
 208. Melendez RI, Rodd-Henricks ZA, Engleman EA, Li TK, McBride WJ, et al. Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol. *Alcohol Clin Exp Res.* 2002; 26:318–325. [PubMed: 11923583]
 209. Gatto GJ, McBride WJ, Murphy JM, Lumeng L, Li TK. Ethanol self-infusion into the ventral tegmental area by alcohol-preferring rats. *Alcohol.* 1994; 11:557–564. [PubMed: 7865158]
 210. Engleman EA, Ingraham CM, McBride WJ, Lumeng L, Murphy JM. Extracellular dopamine levels are lower in the medial prefrontal cortex of alcohol-preferring rats compared to Wistar rats. *Alcohol.* 2006; 38:5–12. [PubMed: 16762687]
 211. Franklin KM, Engleman EA, Ingraham CM, McClaren JA, Keith CM, et al. A single, moderate ethanol exposure alters extracellular dopamine levels and dopamine d receptor function in the nucleus accumbens of wistar rats. *Alcohol Clin Exp Res.* 2009; 33:1721–1730. [PubMed: 19572982]
 212. Sahr AE, Thielen RJ, Lumeng L, Li TK, McBride WJ. Long-lasting alterations of the mesolimbic dopamine system after periadolescent ethanol drinking by alcohol-preferring rats. *Alcohol Clin Exp Res.* 2004; 28:702–711. [PubMed: 15166644]
 213. Thielen RJ, Engleman EA, Rodd ZA, Murphy JM, Lumeng L, et al. Ethanol drinking and deprivation alter dopaminergic and serotonergic function in the nucleus accumbens of alcohol-preferring rats. *J Pharmacol Exp Ther.* 2004; 309:216–225. [PubMed: 14718606]
 214. Wozniak KM, Pert A, Mele A, Linnoila M. Focal application of alcohols elevates extracellular dopamine in rat brain: a microdialysis study. *Brain Res.* 1991; 540:31–40. [PubMed: 2054625]
 215. Murphy JM, McBride WJ, Lumeng L, Li TK. Regional brain levels of monoamines in alcohol-preferring and -nonpreferring lines of rats. *Pharmacol Biochem Behav.* 1982; 16:145–149. [PubMed: 6173885]
 216. Murphy JM, McBride WJ, Lumeng L, Li TK. Alcohol preference and regional brain monoamine contents of N/Nih heterogeneous stock rats. *Alcohol Drug Res.* 1987; 7:33–39. [PubMed: 2431698]
 217. Quintanilla ME, Bustamante D, Tampier L, Israel Y, Herrera-Marschitz M. Dopamine release in the nucleus accumbens (shell) of two lines of rats selectively bred to prefer or avoid ethanol. *Eur J Pharmacol.* 2007; 573:84–92. [PubMed: 17651729]

218. Short JL, Drago J, Lawrence AJ. Comparison of ethanol preference and neurochemical measures of mesolimbic dopamine and adenosine systems across different strains of mice. *Alcohol Clin Exp Res.* 2006; 30:606–620. [PubMed: 16573578]
219. Naassila M, Ledent C, Daoust M. Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. *J Neurosci.* 2002; 22:10487–10493. [PubMed: 12451148]
220. El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. *Neurology.* 2003; 61:S82–87. [PubMed: 14663017]
221. Zahniser NR, Simosky JK, Mayfield RD, Negri CA, Hanania T, et al. Functional uncoupling of adenosine A(2A) receptors and reduced response to caffeine in mice lacking dopamine D2 receptors. *J Neurosci.* 2000; 20:5949–5957. [PubMed: 10934242]
222. Datta U, Noailles PA, Rodriguez M, Kraft M, Zhang Y, et al. Accumulation of tyrosine hydroxylase messenger RNA molecules in the rat mesencephalon by chronic caffeine treatment. *Neurosci Lett.* 1996; 220:77–80. [PubMed: 8981477]
223. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. *J Pharmacol Exp Ther.* 1986; 239:219–228. [PubMed: 3761194]




Figure 1.

Daily caffeine intake for female Wistar (light gray bar) and P (dark gray bar) rats given 24-hour continuous access to multiple caffeine concentrations (0.3, and 1.0 mg/ml), with food and water available ad lib ($n = 12/\text{line}$). The total amount reflects the sum of daily intake of 0.3 and 1.0 mg/ml caffeine. * indicates $p < 0.05$ vs. Wistar; +, indicates $p < 0.05$ vs. 0.3 mg/ml caffeine concentration.




Figure 2. Average daily fluid intake (ml/kg) over 2 weeks of 1-hour/day limited access drinking sessions by adult female P rats ($n = 18-30$ /group). * indicates $p < 0.05$ vs. water; + indicates $p < 0.05$ vs. 0.3 mg/ml caffeine; # indicates $p < 0.05$ vs. 15% v/v ethanol.




Figure 3.

A representation of possible neurochemical/molecular sites of interaction between ethanol and caffeine. The MCL DA system includes afferent projections from DA neurons in the VTA to several projections regions, including the mPFC and NAc. Neurons of the mPFC are primarily glutamatergic, whereas the majority of neurons in the NAc are GABAergic medium spiny neurons. While evidence for the effects of caffeinated ethanol in this system is limited, it may be hypothesized that caffeine enhances EtOH's effects, increasing DA and glutamate neurotransmission, while disinhibiting release of these transmitters through reductions in NAc GABA signaling. Taken together, co-administration of caffeine and ethanol may increase the rewarding and reinforcing properties associated with either drug alone. Repeated experience with this drug combination may initiate neural and/or behavioral adaptations. This may have important implications for the transition from recreational alcohol drinking to alcoholism, particularly in populations that exhibit greater vulnerability or predisposition to develop alcohol use disorders.

Table 1

Peak ethanol levels (mg%) and ethanol elimination rate (mg%/min) in female P rats (n = 5–7/group) following acute i.p. exposure to 1 mg/kg caffeine dissolved in 0.5 g/kg 15% w/v ethanol (low), or 30 mg/kg caffeine dissolved in 2.0 g/kg 15% w/v ethanol (high), or equivalent doses of 15% w/v ethanol alone.

Treatment Condition	Ethanol Peak Level (mg%)	Ethanol Elimination(mg%/min)
Ethanol Low	48 ± 5	-0.70 ± 0.05
Ethanol/Caffeine Low	68 ± 6	-0.92 ± 0.14
Ethanol High	235 ± 10	-0.78 ± 0.17
Ethanol/Caffeine High	222 ± 19	-0.68 ± 0.02

* , indicates p < 0.05 vs. ethanol alone group.